StockUS listing USGLMDNASDAQHealthcareCapital Destroyer

Galmed Pharmaceuticals Ltd(GLMD) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk38Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 4.95M
Reward Ratingⓘ34 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ38 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GLMD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Galmed Pharmaceuticals Ltd?

a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications.

AI Brief Pro

The brief on Galmed Pharmaceuticals Ltd

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Galmed Pharmaceuticals Ltd?

a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.95M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.666
Insider Activity
12M windowNo data
No insider activity data available for this ticker.